Contraception required
Effective contraception is required during treatment.
Medicine information MICOFENOLAT MOFETIL TEVA 250mg capsules
- Product code:
- W52874001
- Quantity:
- 100
- Indicated for:
- prevention of transplant rejection
- Route of administration:
- oral
- Substance:
- mycophenolate mofetil (immunosuppressant)
- ATC
- L04AA06 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants
Mycophenolate is an immunosuppressive medication used to prevent organ rejection in transplant recipients, such as kidney, liver, or heart transplants. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids. Mycophenolate works by inhibiting the proliferation of T and B lymphocytes, thereby reducing the immune response against the transplanted organ.
Mycophenolate is available as mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), both of which are taken orally, usually twice daily, as directed by a doctor. The exact dosage depends on the type of transplant and the patient’s condition.
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and infections, as the medication suppresses the immune system. Other side effects may include anemia, leukopenia (low white blood cell count), and an increased risk of severe or opportunistic infections.
Mycophenolate is contraindicated in pregnant women, as it can cause severe birth defects. Women of childbearing age must use effective contraception during treatment and for several weeks after stopping the medication. Regular monitoring is essential to detect potential side effects and adjust the dosage if necessary.
Mycophenolate is available as mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), both of which are taken orally, usually twice daily, as directed by a doctor. The exact dosage depends on the type of transplant and the patient’s condition.
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and infections, as the medication suppresses the immune system. Other side effects may include anemia, leukopenia (low white blood cell count), and an increased risk of severe or opportunistic infections.
Mycophenolate is contraindicated in pregnant women, as it can cause severe birth defects. Women of childbearing age must use effective contraception during treatment and for several weeks after stopping the medication. Regular monitoring is essential to detect potential side effects and adjust the dosage if necessary.
General data about MICOFENOLAT MOFETIL TEVA 250mg
- Substance:
- mycophenolate mofetil
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W52874001
- Strength:
- 250mg
- Pharmaceutical form:
- capsules
- Quantity:
- 100
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for mycophenolate mofetil
Strengths available for mycophenolate mofetil
- 1mg/5ml
- 250mg
- 500mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 15/10/2009
- Source record: last updated
- 10/04/2026
Warnings:
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid live vaccines
Avoid live vaccines during treatment if contraindicated.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Teratogenic / fetal risk
This medicine may affect fetal development.